Based on the most recent guidelines for T2D, especially for patients with increased cardiorenal risk, the clinical opportunity to prescribe SGLT2 inhibitors will likely increase, and further research is therefore needed to investigate the effect of these drugs on clinical parameters, taking into account the background situation of conventional glucose-lowering agents, such as metformin. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.